



Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

October 6, 2025

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.

- **European Society of Gene and Cell Therapy (ESGCT) Congress**

Title: A transformative LDL-cholesterol-lowering *in vivo* CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates

Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET

Session Title: 9A: Gene Editing II, Ex Vivo Applications

Room: Parallel A

Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine

Final Abstract Number: OR069

Abstracts are available to registrants on the [ESGCT website](#). The oral presentation will also be posted to the "[Posters & Presentations](#)" section of the Company's website at the time of the presentation and will remain accessible following the event.

In addition, management will participate in the following upcoming investor conferences in October:

- **H.C. Wainwright Genetic Medicines Virtual Conference**

Format: Fireside Chat

Date: Tuesday, October 14, 7:00 a.m. ET

Location: Virtual

- **Chardan 9th Annual Genetic Medicines Conference**

Panel Discussion: Genome Editing: Next Wave Technologies

Date: Tuesday, October 21, 8:45 a.m. ET

Location: New York, NY

To access a live webcast of the presentations, please visit the "Investors" section of the Company's website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine

As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative *in vivo* medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision *in vivo* gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor and Media Contacts:

ir@editasmed.com

media@editasmed.com



Source: Editas Medicine, Inc.